Network meta-analysis of 28 RCTs in moderate-to-severe ulcerative colitis: upadacitinib, filgotinib and guselkumab gave clinically meaningful IBDQ gains in induction; upadacitinib 30 mg and vedolizumab showed benefits in maintenance.
Meta-analysisn = 28 trials
Katsoula et al. Systematic review and network meta-analysis: evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life